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Machado–Joseph disease is the most frequently found dominantly-inherited cerebellar ataxia. Over-repetition of a CAG trinu-
cleotide in the MJD1 gene translates into a polyglutamine tract within the ataxin 3 protein, which upon proteolysis may trigger
Machado–Joseph disease. We investigated the role of calpains in the generation of toxic ataxin 3 fragments and pathogenesis of
Machado–Joseph disease. For this purpose, we inhibited calpain activity in mouse models of Machado–Joseph disease by
overexpressing the endogenous calpain-inhibitor calpastatin. Calpain blockage reduced the size and number of mutant ataxin
3 inclusions, neuronal dysfunction and neurodegeneration. By reducing fragmentation of ataxin 3, calpastatin overexpression
modified the subcellular localization of mutant ataxin 3 restraining the protein in the cytoplasm, reducing aggregation and
nuclear toxicity and overcoming calpastatin depletion observed upon mutant ataxin 3 expression. Our findings are the first
in vivo proof that mutant ataxin 3 proteolysis by calpains mediates its translocation to the nucleus, aggregation and toxicity and
that inhibition of calpains may provide an effective therapy for Machado–Joseph disease.
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Introduction
Machado–Joseph disease, also known as spinocerebellar ataxia
type 3, was originally described in people of Portuguese descent
and is now considered to be the most frequent form of the auto-
somal dominantly inherited cerebellar ataxias. Machado–Joseph dis-
ease is a neurodegenerative disorder characterized by abnormal
movement (Sudarsky and Coutinho, 1995) and is caused by an
unstable and expanded polyglutamine repeat of 455 CAGs
within the coding region of the causative gene, MJD1, on chromo-
some 14q32.1 (Kawaguchi et al., 1994), conferring a toxic gain of
function to the ubiquitin-binding protein ataxin 3 (ATXN3)
(Rubinsztein et al., 1999; Wang et al., 2000; Burnett et al., 2003;
Doss-Pepe et al., 2003; Scheel et al., 2003; Chai et al., 2004).
Ataxin 3 is a protein of 42 kDa and is predominantly expressed
cytoplasmatically (Paulson et al., 1997a; Schmidt et al., 1998),
even though it is small enough to enter the nucleus through pas-
sive diffusion (Marfori et al., 2011). Upon polyglutamine expan-
sion, in spite of the increase in its molecular weight which could
hinder access to the nucleus, mutant ataxin 3 accumulates in ubi-
quitinated intranuclear inclusions (Paulson et al., 1997b). The toxic
fragment hypothesis predicts that proteolytic cleavage of the
full-length polyglutamine protein initiates the aggregation process
associated with inclusion formation and cellular dysfunction
(Haacke et al., 2006; Takahashi et al., 2008).
A toxic cleavage fragment of mutant ataxin 3 was first proposed
to trigger neurodegeneration by Ikeda et al. (1996). Indeed, the
C-terminal fragment of mutant ataxin 3 is more toxic than the
full-length protein (Ikeda et al., 1996; Paulson et al., 1997b; Goti
et al., 2004). Understanding the proteolytic mechanism involved
and the cellular protease(s) responsible could unravel the trigger
mechanism for Machado–Joseph disease and reveal potential tar-
gets for therapy. Haacke and colleagues observed in cell lysates
that upon calcium influx, ataxin 3 was proteolysed by calpains in
fragments that could escape cytoplasmic quality control (Haacke
et al., 2007; Breuer et al., 2010). This observation was recently
confirmed in patient specific induced pluripotent stem cell-derived
neurons (Koch et al., 2011). Calpain regulation is therefore critical
and can come about by binding to calpastatin, the only endogen-
ous calpain-specific inhibitor identified thus far (Takano et al.,
2005). How ataxin 3 cleavage fragments mediate neurotoxicity
has not been evaluated in animal models of Machado–Joseph dis-
ease. Overactivation of calpains may contribute decisively to the
pathology by increasing cleavage of ataxin 3 into fragments con-
taining the expanded polyglutamine segment, which may be able
to penetrate the nuclear pore, accumulate in the nucleus and
induce neurodegeneration.
Herein, taking advantage of adeno-associated (AAV) viral vec-
tors for overexpression of calpastatin, we set out to investigate in
a lentiviral mouse model of Machado–Joseph disease (Alves et al.,
2008) and transgenic mice overexpressing calpastatin (Takano
et al., 2005) whether and how calpains are involved in the patho-
genesis of the disease. We provide in vivo evidence that: (i) pro-
teolysis by calpains is required for nuclear localization of mutant
ataxin 3; (ii) inhibition of calpains significantly decreases neuronal
dysfunction and neurodegeneration in a mouse model of
Machado–Joseph disease; (iii) production of mutant ataxin 3
cleavage fragments and the resulting nuclear localization inversely
correlate with calpastatin levels in a dose-dependent manner; and
(iv) calpastatin is depleted from neurons bearing mutant ataxin 3
intranuclear inclusions. In conclusion, we provide new insights into
mutant ataxin 3 proteolysis, nuclear translocation and a resulting
role in the pathogenesis of Machado–Joseph disease, which indi-
cate that calpain inhibition may provide a new avenue of therapy.
Materials and methods
Animals
Four-week-old C57BL/6J mice (Charles River) were used. The animals
were housed in a temperature-controlled room maintained on a 12 h
light/12 h dark cycle. Food and water were provided ad libitum. The
experiments were carried out in accordance with the European
Community directive (86/609/EEC) for the care and use of laboratory
animals. The researchers received adequate training (Felasa-certified
course) and certification to perform the experiments from the
Portuguese authorities (Direcc¸a˜o Geral de Veterina´ria).
Human brain tissue
Post-mortem human brain tissue from dentate nucleus was ob-
tained from the tissue donation program of the National Ataxia
Foundation, Minneapolis, MN, USA (VA Medical Centre and Albany
Medical College). The tissues included a control patient (female,
36 years) and three patients with Machado–Joseph disease: Patient
O (female, 70 years, 67/23 CAG repeats); Patient W (female,
62 years, 74/22 CAG repeats); and Patient K (male, 53 years, 69/23
CAG repeats).
Machado–Joseph disease transgenic
mice tissue
Cerebella of Machado–Joseph disease transgenic mice (5.5 and 15
weeks old, n = 2 and n = 4, respectively) (Torashima et al., 2008;
Oue et al., 2009) expressing a truncated form of human ataxin 3
with 69 CAG repeats, and wild-type mice (n = 3; 20 weeks old) of
an older offspring were dissected and treated for western blot analysis.
Production of viral vectors
Lentiviral vectors encoding human wild-type ataxin 3 (ATX-3 27Q) or
mutant ataxin 3 (ATX-3 72Q) (Alves et al., 2008) were produced in
293T cells with a four-plasmid system, as previously described (de
Almeida et al., 2001). The lentiviral particles were resuspended in
1% bovine serum albumin in PBS. The viral particle content of batches
was determined by assessing HIV-1 p24 antigen levels (Retro Tek,
Gentaur). Viral stocks were stored at 80C.
AAV vectors were produced as previously described (Zolotukhin
et al., 1999; Kugler et al., 2003).
In vivo injection into the striatum
Concentrated viral stocks were thawed on ice. Lentiviral vectors
encoding human wild-type (ATX-3 27Q) or mutant ataxin 3 (ATX-3
72Q) were stereotaxically injected into the striatum at the following
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coordinates: antero-posterior: + 0.6 mm; lateral: 1.8 mm; ventral:
3.3 mm; tooth bar: 0. Animals were anaesthetized by administration
of avertin (10ml/g intraperitoneally).
Wild-type and transgenic mice overexpressing calpastatin received a
single 1 ml injection of 0.2 mg p24/ml lentivirus in each side: left hemi-
sphere (ATX-3 27Q) and right hemisphere (ATX-3 72Q). Wild-type
mice were co-injected with 1 ml of 0.4 mg p24/ml ataxin 3 72Q lenti-
virus and 3 ml of AAV1/2-green fluorescent protein (AAV1/2-GFP; left
hemisphere) or AAV2-calpastatin (AAV2-CAST; right hemisphere).
For the western blot procedure, transgenic mice overexpressing cal-
pastatin received a single 2 ml injection of 0.3 mg p24/ml lentivirus in
each side: left hemisphere (ATX-3 27Q) and right hemisphere (ATX-3
72Q). Wild-type mice were co-injected with 1 ml of 0.6 mg of p24/ml
ATX-3 72Q lentivirus and 4 ml of AAV1/2-GFP (left hemisphere) or
AAV2-CAST (right hemisphere).
Mice were kept in their home cages for 4, 5 or 8 weeks before
being sacrificed for immunohistochemical or western blot analysis.
Imunohistochemical procedure
After an overdose of avertin (2.5 times, 12 ml/g given intraperitone-
ally), transcardial perfusion of the mice was performed with a phos-
phate solution followed by fixation with 4% paraformaldehyde. The
brains were removed and post-fixed in 4% paraformaldehyde for 24 h
and cryoprotected by incubation in 25% sucrose/phosphate buffer for
48 h. The brains were frozen and 25 mm coronal sections were cut
using a cryostat (LEICA CM3050 S) at 21C. Slices throughout the
entire striatum were collected in anatomical series and stored in
48-well trays as free-floating sections in PBS supplemented with
0.05 mM sodium azide. The trays were stored at 4C until immunohis-
tochemical processing.
Sections from injected mice were processed with the following pri-
mary antibodies: a mouse monoclonal anti-ataxin 3 antibody (1H9;
1:5000; Chemicon), recognizing the human ataxin 3 fragment from
amino acids F112 to L249; a rabbit polyclonal anti-ubiquitin antibody
(Dako, 1:1000); a mouse monoclonal anti-myc tag antibody, clone
4A6 (1:1000; Upstate, Cell Signalling Solutions); and a rabbit anti-
dopamine- and cyclic AMP-regulated neuronal phosphoprotein
(DARPP-32) antibody (1:1000; Chemicon), followed by incubation
with the respective biotinylated secondary antibodies (1:200; Vector
Laboratories). Bound antibodies were visualized using the
VECTASTAIN ABC kit, with 3,30-diaminobenzidine tetrahydrochloride
(DAB metal concentrate; Pierce) as substrate.
Double stainings for ataxin 3 (1H9; 1:3000), nuclear marker [DAPI
(40,6-diamidino-2-phenylindole), blue] and ubiquitin (Dako, 1:1000) or
calpastatin (H300, 1:250, Santa Cruz) were performed. Free-floating
sections from injected mice were incubated at room temperature for
2 h in PBS/0.1% TritonTM X-100 containing 10% normal goat serum
(Gibco), and then overnight at 4C in blocking solution with the pri-
mary antibodies. Sections were washed three times and incubated for
2 h at room temperature with the corresponding secondary antibodies
coupled to fluorophores (1:200, Molecular Probes) diluted in the re-
spective blocking solution. The sections were washed three times and
then mounted in FluorSaveTM Reagent (Calbiochem) on microscope
slides.
Staining was visualized using Zeiss Axioskop 2 plus, Zeiss Axiovert
200 and Zeiss LSM 510 Meta imaging microscopes (Carl Zeiss
Microimaging), equipped with AxioCam HR colour digital cameras
(Carl Zeiss Microimaging) using 5 , 20 , 40 and 63
Plan-Neofluar and a 63 Plan/Apochromat objectives and the
AxioVision 4.7 software package (Carl Zeiss Microimaging).
Quantitative analysis of fluorescence was performed with a semi-
automated image-analysis software package (ImageJ software).
Cresyl violet staining
Coronal 25mm thick striatal sections were cut using a cryostat.
Pre-mounted sections were stained with cresyl violet for 30 s, differ-
entiated in 70% ethanol, dehydrated by passing twice through 95%
ethanol, 100% ethanol and xylene solutions and mounted onto micro-
scope slides with Eukitt (Sigma).
Evaluation of the volume of the
dopamine- and cAMP-regulated
neuronal phosphoprotein depleted
volume
The extent of ataxin 3 lesions in the striatum was analysed by photo-
graphing, with a 1.25 objective, eight DARPP-32 stained sections
per animal (25mm thick sections at 200mm intervals), selected to
obtain complete rostrocaudal sampling of the striatum, and by quan-
tifying the area of the lesion with a semi-automated image analysis
software package (ImageJ). The volume was then estimated with the
following formula: volume = d(a1 + a2 + a3. . .), where d is the dis-
tance between serial sections (200 mm) and a1 + a2 + a3 are
DARPP-32 depleted areas for individual serial sections (de Almeida
et al., 2002).
Cell counts and morphometric analysis
of ataxin 3 and ubiquitin inclusions
Coronal sections showing complete rostrocaudal sampling (one of
eight sections) of the striatum were scanned with a 20 objective.
The analysed areas of the striatum encompassed the entire region
containing ataxin 3 and ubiquitin inclusions, as revealed by staining
with the anti-ataxin 3 and anti-ubiquitin antibodies. All inclusions were
manually counted using a semiautomated image-analysis software
package (ImageJ). Inclusions diameter was assessed by scanning the
area above the needle tract in four different sections, using a 63
objective. At least 100 inclusions showing double staining for mutant
ataxin 3 and GFP or calpastatin were analysed using LSM Image
Browser.
Western blot analysis
For assessment of ataxin 3 proteolysis in the lentiviral model of
Machado–Joseph disease, transcardial perfusion of the mice was
performed with ice-cold PBS containing 10 mM EDTA (ethylenediami-
netetraacetic acid) and 10 mM of the alkylating reagent
N-ethylmaleimide, to avoid post-mortem calpain overactivation. The
injected striata were then dissected and immediately sonicated in
radioimmunoprecipitation assay buffer [50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 7 mM EDTA, 1% NP-40 (nonyl phenoxypolyethoxy-
lethanol), 0.1% SDS, 10mg/ml DTT (dithiothreitol), 1 mM PMSF (phe-
nylmethylsulphonyl fluoride), 200 mg/ml leupeptin, protease inhibitors
cocktail]. Equal amounts (30 mg of protein) were resolved on 12%
SDS–PAGE and transferred onto PVDF (polyvinylidene fluoride)
membranes. Immunoblotting was performed using the monoclonal
anti-ataxin 3 antibody (1H9, 1:1000; Chemicon), anti-calpastatin
(H300, 1:200; Santa Cruz), anti-calpain-cleaved -spectrin
(Roberts-Lewis et al., 1994) (Ab 38, 1:3000) and anti-actin (clone
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AC-74, 1:5000; Sigma) or anti-tubulin (clone SAP.4G5, 1:15 000;
Sigma). A partition ratio with actin or tubulin was calculated following
quantification with Quantity One 1-D image analysis software ver-
sion 4.5.
Statistical analysis
Statistical analysis was performed using Student’s t-test or ANOVA for
multiple comparisons. Values of P5 0.05 were considered statistically
significant.
Results
Inhibition of calpains in a lentiviral
mouse model of Machado–Joseph
disease reduces the size and number
of neuronal intranuclear inclusions of
mutant ataxin 3
In order to investigate the role of calpains in the pathogenesis of
spinocerebellar ataxia type 3, we overexpressed the calpain inhibi-
tor calpastatin in a lentiviral mouse model of Machado–Joseph
disease (Alves et al., 2008). Four-week-old mice were co-injected
bilaterally in the striatum with lentiviral vectors encoding ATX-3
72Q and AAV vectors encoding GFP (control, left hemisphere) or
calpastatin (right hemisphere; Fig. 1) and were sacrificed 8 weeks
post-injection. Mice singly injected with calpastatin and GFP were
used as a control of AAV transduction. AAV vectors mediate a
delayed expression of calpastatin, when compared with a quicker
onset of ataxin 3 expression upon lentiviral transduction, due to
the necessity of conversion of the single-stranded genome into
double stranded DNA, especially in non-dividing cells (Shevtsova
et al., 2005). Therefore, co-injection of both viral vectors in the
mouse brain allowed cells co-transduction in a phased manner,
leading to the development of pathology before maximum expres-
sion of the calpain inhibitor 2 weeks later.
Calpain inhibition by calpastatin reduced the size and number
of mutant ataxin 3 (ATX-3 72Q) inclusions (Figs 2B, D and K
and 4E) when compared to the GFP transduced hemisphere
(Figs 2A, C and K and 4E). In this control hemisphere (Fig.
2C) and in cells not infected by calpastatin (Fig. 2D; arrow-
head), ATX-3 72Q accumulated in large intranuclear inclusions
with 3.98mm mean diameter and co-localized with ubiquitin
(Fig. 2E–G). On the contrary, upon calpastatin overexpression,
mutant ataxin 3 inclusions became very small, almost undetect-
able by fluorescence immunohistochemistry (Fig. 2D), and ubi-
quitin pattern was diffuse (Fig. 2H–J). Calpain inhibition
promoted a 2.9-fold reduction in inclusions diameter to 1.4 mm
(Figs 2C and D and 4E) and reduced to 47% the number of
N-terminal ataxin 3 inclusions detected with an anti-myc anti-
body (Fig. 2A, B and K), an effect that was less prominent
when inclusions were counted in brightfield upon imunohisto-
chemistry with the 1H9 (recognizes amino acids 221–224) or
anti-ubiquitin antibodies (data not shown). This may be due to
the fact that the C-terminal of ataxin 3, including the polyglu-
tamine tract, is more prone to aggregation.
Upon co-infection with vectors encoding wild-type ataxin 3
(ATX-3 27Q) and GFP (left hemisphere) or calpastatin (right hemi-
sphere; Fig. 1), neither ataxin 3 nor ubiquitin inclusions were
observed. Furthermore, no difference in the subcellular localization
of ATX-3 27Q was observed between the two hemispheres (data
not shown).
These results suggest that inhibition of calpain activity in the
mouse brain prevents accumulation of mutant ataxin 3 in large
intranuclear inclusions.
A
B
C
D
E
F
Figure 1 Strategy used to generate an in vivo mouse model of
Machado–Joseph disease and to inhibit mutant ataxin 3 prote-
olysis by calpains. Schematic representation of the lentiviral (LV)
constructs used in the development of the mouse model of
Machado–Joseph disease. Complementary DNAs encoding
(A) wild-type (27 CAG repeats) or (B), mutant ataxin 3 (72
CAG repeats) were cloned in the SIN-W transfer vector.
(C) Schematic of the AAV1/2 encoding GFP. (D) The comple-
mentary DNA encoding calpastatin was inserted into an AAV
serotype 2 backbone, under the control of the human synapsin 1
gene promoter, which restrains expression to neurons.
(E) Four-week-old mice were co-injected bilaterally in the stri-
atum with ATX3-72Q and GFP (left hemisphere) or calpastatin
(right hemisphere) vectors and were sacrificed 5 and 8 weeks
post-injection for western blot and immunohistochemical ana-
lysis, respectively (injection co-ordinates: antero-posterior:
+ 0.6 mm; lateral: 1.8 mm; ventral: 3.5 mm; tooth bar: 0).
(F) Diagram of ataxin 3 showing antibody recognition sites used
in Fig. 5. hSYN = human synapsin 1; ITR = inverted terminal
repeat; LTR = long terminal repeat; NES = nuclear export signal;
NLS = nuclear localization signal; PGK = phosphoglycerate
kinase.
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Inhibition of calpains in a lentiviral
mouse model of Machado–Joseph
disease mediates striatal
neuroprotection
To monitor the effects of calpastatin overexpression over neuronal
dysfunction induced by mutant ataxin 3 we performed an immu-
nohistochemical analysis for DARPP-32, a regulator of dopamine
receptor signalling (Greengard et al., 1999) which we have previ-
ously shown to be downregulated in the striatum of lentiviral and
transgenic Machado–Joseph disease animal models (Alves et al.,
2008). Loss of DARPP-32 immunoreactivity in the calpastatin in-
jected striatal hemisphere was reduced to 39% when compared
with the GFP transduced hemisphere (Fig. 3A–D and G), whereas
no loss of DARPP-32 staining was detected in mice co-injected
with ATX-3 27Q and GFP or calpastatin (data not shown). This
is indicative of a neuroprotective effect provided by the selective
inhibition of calpains.
Additionally, cresyl violet-stained sections further demonstrated
a significant reduction in the number of shrunken hyperchromatic
nuclei upon calpastatin overexpression (Fig. 3E, F and H), indicat-
ing that calpain inhibition prevents cell injury and striatal degen-
eration induced by mutant ataxin 3 expression in the brain of
adult mice.
Calpastatin prevents nuclear
translocation of mutant ataxin 3 in
a dose-dependent manner
We further assessed the involvement of calpains in the pathogen-
esis of Machado–Joseph disease by expressing mutant ataxin 3 in
the mouse striatum upon three progressively increasing levels of
calpastatin (Fig. 4), as follows: (i) wild-type animals; (ii) transgenic
mice overexpressing calpastatin (Takano et al., 2005) and
(iii) animals injected with AAV vectors encoding calpastatin.
The mean diameter of mutant ataxin 3 intranuclear inclusions
was reduced to 2.77mm in transgenic animals (Fig. 4B and E),
1.4-fold smaller than the control, but 2-fold larger than the
mean inclusion size when calpastatin levels were achieved by
viral transduction (Fig. 4C and E). Fig. 4D shows the increasing
calpastatin protein levels in transgenic mice overexpressing calpas-
tatin and AAV2-calpastatin injected mice.
These results suggest that a critical concentration of calpastatin is
necessary to completely inhibit calpain activity in order to prevent
mutant ataxin 3 translocation to the nucleus and aggregation.
Figure 2 Inhibition of calpains significantly decreases the
number of N-terminal mutant ataxin 3 inclusions, while changing
mutant ataxin 3 and ubiquitin aggregation pattern. (A–K)
Co-expression of mutant ataxin 3 and GFP (left hemisphere) or
calpastatin (right hemisphere) in the striatum of adult mice, 2
months post-injection. (A and B) Peroxidase staining using an
anti-myc antibody to the myc tag of the N-terminal ataxin 3 (Ab
clone 4A6). A significant decrease in the number of N-terminal
ataxin 3 inclusions was observed in calpastatin transduced
hemisphere. (C) Fluorescence staining for mutant ataxin 3 (Ab
1H9, red) localization upon co-expression with GFP (green) or (D)
calpastatin (Ab H300, green). Nuclear marker (DAPI, blue) was
used. As expected, in the GFP transduced hemisphere mutant
ataxin 3 was observed as intranuclear inclusions. On the contrary,
the cells infected with AAV2-calpastatin showing calpastatin
immunoreactivity, presented small inclusions almost not de-
picted. (E–G) Fluorescence staining for co-localization (G and J)
merge of E and F or H and I with nuclear marker DAPI (blue) of
mutant ataxin 3 (E and H, Ab 1H9, green) and ubiquitin (F and I,
Figure 2 Continued
antibody anti-ubiquitin DAKO, red). While in the control hemi-
sphere mutant ataxin 3 intranuclear inclusions (E) were ubiqui-
tinated (F) particularly within the central core, (H–J) ubiquitin
pattern upon calpastatin overexpression was rather diffuse. (K)
Quantification of the absolute number of myc-positive cells,
graph related to panels (A and B). Statistical significance was
evaluated with Student’s t-test (n = 4, *P = 0.05).
SEM = standard error of the mean, CAST = calpastatin.
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Inhibition of calpains reduces ataxin 3
proteolysis
To investigate the mechanism by which calpain inhibition modified
the subcellular localization of mutant ataxin 3, thereby preventing
its nuclear localization, neuronal dysfunction and neurodegenera-
tion, we performed western blot analysis of brain punches of mice
subjected to the previously described experimental paradigm
(Fig. 1E) but sacrificed at an earlier time point: 5 weeks
post-injection. Striatal punches of non-injected and ATX-3 27Q
transduced hemispheres were used as controls. Importantly, two
ataxin 3 fragments of 26 and 34 kDa were strongly detected in
the brain hemispheres expressing mutant ataxin 3 (Fig. 5A; arrow-
heads), but sparingly and not detected, respectively, in those
overexpressing wild-type and only expressing endogenous
ataxin 3 (Fig. 5D); thus confirming in vivo that mutant ataxin 3
is cleaved into fragments that accumulate in the brain and that a
wild-type fragment may be more rapidly degraded. Notably, in-
hibition of calpains activity, confirmed by a decreased immunola-
belling of calpain-cleaved -spectrin (Ab 38; Fig. 5E), a natural
substrate of calpains, decreased by 39% the production of the
26 kDa mutant ataxin 3 fragment (Fig. 5A and F), which was
also detected using a N-terminal antibody (Ab myc; Fig. 5C) and a
C-terminal antibody specific for the polyglutamine stretch (Ab
1C2; Fig. 5B). In addition, the formation of the 34 kDa fragment
was also decreased by 17%, being this fragment only C-terminal
and only generated from the mutant protein (Fig. 5G).
These results are in accordance with the ‘toxic fragment hypoth-
esis’ and strongly support the idea that inhibition of ataxin 3 cleav-
age by calpains may be the basis of the calpastatin
neuroprotective mechanism.
Calpastatin is depleted from cells with
mutant ataxin 3 intranuclear inclusions
Progression of Machado–Joseph disease could be propelled by de-
pletion of calpastatin, which would accelerate calpains dysregula-
tion and lead to neurodegeneration. To investigate this hypothesis,
we evaluated the immunoreactivity for calpastatin upon expression
of mutant ataxin 3 in the previously described calpastatin trans-
genic mice (Takano et al., 2005). Whereas a strong calpastatin
immunoreactivity was observed in the hemisphere transduced
with lentiviral vectors encoding ATX-3 27Q, a significant reduction
of calpastatin immunostaining by 18%, was observed in cells
Figure 3 Inhibition of calpains prevents cell injury and striatal degeneration. (A–H) Co-expression of mutant ataxin 3 (ATX-3 72Q) and
GFP (left hemisphere) or calpastatin (CAST, right hemisphere) in the striatum of adult mice, 2 months post-injection. (A–D) Peroxidase
staining using an anti-DARPP-32 antibody. (C and D) Higher magnification of A and B. (A and C) A major loss of DARPP-32 immu-
noreactivity was observed in the striatum infected with ATX-3 72Q and GFP (B and D), whereas minor DARPP-32 loss was observed in the
striatum infected with ATX-3 72Q and calpastatin. (E and F) Cresyl violet staining of (E) ATX-3 72Q + GFP and (F) ATX-3
72Q + calpastatin transduced hemispheres of adult mice. (G) Quantification analysis of the DARPP-32-depleted region in the brains of
mice. The lesion volume in the hemisphere infected with ATX-3 72Q and calpastatin was much smaller than that in the hemisphere
infected with ATX3-72Q and GFP, indicative of a neuroprotective effect conferred by the inhibition of calpains (n = 4, *P = 0.05). (H)
Quantification analysis of the pyknotic nuclei visible in both hemispheres on cresyl violet-stained sections. More pyknotic nuclei were
visible in the GFP transduced hemisphere, suggesting that calpastatin prevented cell injury and striatal degeneration after co-injection with
ATX-3 72Q. All the pictures were taken around the injection site area and show representative immunohistochemical stainings. Statistical
significance was evaluated with Student’s t-test (n = 4, **P5 0.01). SEM = standard error of the mean.
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where mutant ataxin 3 inclusions were present (Fig. 6A–F and J).
Interestingly, in Fig. 6F, the cell highlighted with an arrow, where
no ataxin 3 inclusions were observed, presented a similar calpastatin
immunolabeling to those transduced with ATX3 27Q, contrasting
with the reduced immunostaining detected in the cells pointed
with arrowheads with large ataxin 3 intranuclear inclusions.
Calpastatin depletion was further confirmed by immunoblot
analysis of brains from calpastatin transgenic mice (Fig. 6G and
K). Calpastatin levels were reduced by 26% in the hemisphere
where mutant ataxin 3 was overexpressed in comparison to the
contra-lateral hemisphere with wild-type ataxin 3 overexpression.
To validate calpastatin depletion in Machado–Joseph disease we
analysed calpastatin levels in patient post-mortem tissue and in
a transgenic mouse model of the disease using western blot
(Torashima et al., 2008; Oue et al., 2009). A dramatic 68% re-
duction of calpastatin levels was found in the transgenic mouse
model, when compared with wild-type mice (Fig. 6H and L).
Importantly, in human tissue we observed that calpastatin levels
were reduced by 67, 25 and 7% in samples from dentate nucleus
of three patients with Machado–Joseph disease compared with the
control (Fig. 6I and M).
These results indicate that upon mutant ataxin 3 expression,
calpastatin is depleted, which may in turn increase calpain activity,
ataxin 3 proteolysis, nuclear translocation, aggregation and tox-
icity, ultimately triggering or at least severely aggravating the
pathogenesis of Machado–Joseph disease.
Figure 4 Inhibition of calpains prevents nuclear translocation and aggregation of mutant ATX-3 in a dose dependent manner. Subcellular
localization of mutant ataxin 3 (ATX-3 72Q, Ab 1H9, red) when co-injected with GFP (green, n = 4; A), in transgenic mice overexpressing
calpastatin (Tg hCAST, n = 8; B) and when co-injected with calpastatin (CAST, Ab H300, green, n = 4; C and D). Nuclear marker (DAPI,
blue) was used. As the levels of calpastatin increased (A to B and B to C), aggregation in the nucleus was prevented. (D) Calpastatin
immunoreactivity (CAST, Ab H300, green) is lower in wild-type (wt) and transgenic mice overexpressing calpastatin (Tg hCAST) than in
AAV-2 calpastatin injected mice. (E) Analysis of inclusion diameters showing double staining for mutant ataxin 3 with Ab 1H9 and GFP or
calpastatin (***P50.0001).
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Discussion
In this work, we provide in vivo evidence that calpains are pro-
teolytic enzymes involved in the pathogenesis of Machado–Joseph
disease and that inhibition of calpains reduces cleavage of mutant
ataxin 3, its translocation to the nucleus, aggregation in nuclear
inclusions, neurotoxicity and neurodegeneration.
The neurotoxicity associated with Machado–Joseph disease has
been proposed to be derived from a mutant ataxin 3 cleavage
Figure 5 Ataxin 3 proteolysis in the lentiviral mouse model of Machado–Joseph disease is decreased upon calpastatin overexpression. At
5 weeks post-injection, mice (n = 7) co-injected bilaterally with mutant ataxin 3 (ataxin 3 72Q) and GFP (left hemisphere) or calpastatin
(CAST, right hemisphere) were sacrificed and punches of the striatum were made to perform a western blot analysis with several
antibodies to detect different epitopes of ataxin 3 protein: (A) Ab 1H9, which recognizes amino acids E214-L233; (B) Ab 1C2, specific for
the polyglutamine stretch, present at the C-terminal of ataxin 3; and (C) Ab myc, which recognizes the myc tag located at the N-terminal
of mutant ataxin 3. Two fragments of 26 and 34 kDa were detected (empty and shaded arrowheads, respectively). (D) Striatal punches
of non-injected and ataxin 3 27Q transduced hemispheres. (E) Levels of calpastatin (CAST, antibody H300) and of calpain-cleaved
-spectrin (antibody 38) are also shown. (F and G) Densitometric quantification of 26 and 34 kDa fragments levels of mutant ataxin 3
relative to actin, shown in panel A (n = 7, *P = 0.05). The 26 kDa fragment is clearly detected by Ab 1H9, Ab 1C2 and anti-myc in the
mutant ataxin 3 sample, but faintly in the transgenic wild-type and not detected in the endogenous ataxin 3 sample. The 34 kDa
fragment is only detected in the mutant ataxin 3 sample using Ab 1H9 and Ab 1C2. SEM = standard error of the mean.
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fragment (Ikeda et al., 1996; Haacke et al., 2006; Takahashi
et al., 2008; Koch et al., 2011), which above a critical concentra-
tion becomes cytotoxic (Goti et al., 2004). Based on cell or in vitro
models, mutant ataxin 3 has been reported to be a substrate for
caspases (Berke et al., 2004; Jung et al., 2009), subject to auto-
lytic cleavage (Mauri et al., 2006) and a substrate for calpains
(Haacke et al., 2007; Koch et al., 2011). An additional cleavage
site was proposed in a mouse model, within the N-terminus of
amino acid 190, which might be neither a caspase nor a calpain
product (Colomer Gould et al., 2007).
To clarify this issue, we overexpressed the endogenous
calpain-specific inhibitor calpastatin in a lentiviral mouse model
of Machado–Joseph disease and used transgenic mice over-
expressing calpastatin (Takano et al., 2005). This approach over-
comes the use of synthetic peptidic, peptide-mimetic and
non-peptidic calpain inhibitors currently available, which have
problems of specificity, metabolic stability, water-solubility and/
or penetration through the blood–brain barrier (Higuchi et al.,
2005). Instead of using the lentiviral model in the rat (Alves
et al., 2008), here we generated an analogous model in C57BL/
6J mice that allows comparison of results with those obtained in
the transgenic mice overexpressing calpastatin, and to previous
in vivo studies.
As expected, upon mutant ataxin 3 expression, the expanded
protein accumulated as intranuclear inclusions co-localizing with
ubiquitin in the mouse brain (Fig. 2C and E–G). A marked loss
of DARPP-32 immunoreactivity and a large number of pyknotic
nuclei were observed (Fig. 3), suggesting cell injury and neurode-
generation. In contrast, when mutant ataxin 3 was co-injected
with calpastatin to specifically inhibit calpains, a robust and
dose-dependent decrease in the size and number of C- and
N-terminal ataxin 3 inclusions, respectively, (Fig. 2A, B and K)
was observed. In addition, the volume of the region depleted of
DARPP-32 immunoreactivity and the number of pyknotic nuclei
were significantly and robustly decreased (Fig. 3), indicating that
calpain inhibition prevents cell injury and provides
neuroprotection.
Cleavage fragments of mutant ataxin 3, whose existence has
been controversial, were clearly detected in vivo in this study.
While we were finalizing this work, a study in patient-specific
induced pluripotent stem cell-derived neurons also reported the
formation of cleavage fragments of mutant ataxin 3 upon L-glu-
tamate or NMDA (N-methyl-D-aspartate) stimulus (Koch et al.,
2011). The two studies are concordant on providing compelling
evidence of the involvement of calpains in Machado–Joseph dis-
ease, but not on the trigger for calpain activation, as in our study,
cleavage of mutant ataxin 3 occurred without overstimulation of
glutamate receptors.
Cleavage of mutant ataxin 3 (Fig. 5) might occur at amino acid
220 (Fig. 1), giving rise to two different fragments of similar mo-
lecular weight detected by Ab 1H9 (Fig. 5A), which recognizes the
human ataxin 3 fragment from amino acids E214-L233, Ab myc
(Fig. 5C), an antibody for a myc tag located at the N-terminal of
the protein and Ab 1C2 (Fig. 5B), an antibody specific for the
polyglutamine stretch, present at ataxin 3 C-terminal (Fig. 1F). A
simultaneous cleavage at amino acids 60 and 260 proposed by
Haacke et al. (2007) may lead to the final 26 kDa fragment,
detected by Ab 1H9. Cleavage at amino acid 154 may generate
a mutant C-terminal 34 kDa fragment only detected by Ab 1H9
(Fig. 5A) and Ab 1C2 (Fig. 5B), but not by Ab myc (Fig. 5C).
These results support the toxic fragment hypothesis indicating
that calpastatin promotes neuroprotection by decreasing mutant
ataxin 3 fragment production, suggesting that the pathogenesis
of Machado–Joseph disease is strongly associated with mutant
ataxin 3 proteolysis by calpains. As evidenced by the decreased
cleavage of -spectrin, a potential biomarker for neuronal cell
injury (Liu et al., 2008) and ataxin 3 (Fig. 5A and E), upon cal-
pastatin overexpression, proteolysis of other substrates might also
be inhibited as well as other functions regulated by calpains under
pathological conditions not addressed in our studies. Recent evi-
dences suggest that not only the C-terminal fragment is cytotoxic
(Ikeda et al., 1996; Goti et al., 2004), but that the
non-polyglutamine containing ataxin 3 N-terminus fragment is
also toxic and may contribute to an impaired unfolded protein
response in the pathogenesis of Machado–Joseph disease
(Hubener et al., 2011). Our results show that calpastatin
overexpression leads to a decrease of both fragments formation.
Further evidence that calpastatin exerted neuroprotection may
also be drawn from the subcellular localization of the ataxin 3
species.
Ataxin 3, when non-expanded, is enriched in the cytoplasm
(Paulson et al., 1997a; Schmidt et al., 1998; Goti et al., 2004),
but upon polyglutamine expansion the protein accumulates in
the nucleus. This nuclear localization is required for the in vivo
manifestation of Machado–Joseph disease neuropathology.
Accordingly, transgenic mice with 148 CAGs but attached to a
nuclear export signal only develop a milder phenotype with few
inclusions (Bichelmeier et al., 2007). However, how ataxin 3
enters the nucleus under pathogenic conditions and forms aggre-
gates is a matter of debate. It has been proposed that
CK2-dependent phosphorylation determines cellular localization
(Mueller et al., 2009) and that proteotoxic stress increases
nuclear localization of ataxin 3 (Reina et al., 2010), while other
reports underline the importance of nuclear localization (NLS282)
and nuclear export (NES 77 and 141) signals to ataxin 3 intra-
cellular localization (Antony et al., 2009; Macedo-Ribeiro et al.,
2009). Accordingly, we found that the number of inclusions
detected with the antibody targeting the N-terminal ataxin 3
was significantly lower than the amount found when using the
1H9 antibody (amino acids 221–224) in both GFP and
calpastatin-transduced hemispheres. This suggests that the
C-terminal fragment, including the nuclear localization signal
and the polyglutamine stretch, is more prone to aggregation
and accumulates in higher extension in the nucleus as compared
to the N-terminal fragment carrying the nuclear export signal
sequences (Schmidt et al., 1998; Goti et al., 2004; Koch et al.,
2011; Walsh et al., 2005). Furthermore, our results show that
proteolysis of mutant ataxin 3 by calpains is required for its trans-
location to the nucleus in a dose-dependent manner (Fig. 4). As
calpastatin levels increase, the diameter of mutant ataxin 3 inclu-
sions progressively decreases (Fig. 4A: 3.98 mm; B: 2.77mm; and
C: 1.40mm). Our results suggest that calpains cleavage between
the nuclear export signals and the nuclear localization signal dis-
cussed above may account for the enhanced transport of the
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Figure 6 Calpastatin is depleted from cells with mutant ataxin 3 intranuclear inclusions. Transgenic mice overexpressing calpastatin
(Tg hCAST) were injected bilaterally: wild-type ataxin 3 (ataxin 3 27Q) in the left hemisphere and mutant ataxin 3 (ataxin 3 72Q) in the
right hemisphere and were sacrificed 4 weeks post-injection for (A-F,J), immunohistochemistry and (G,K), western blot analysis (n = 6; H).
(A–F) Fluorescence staining for ataxin 3 (Ab 1H9, red; A and D), and in B and E, calpastatin (CAST, Ab H300, green) and nuclear marker
(DAPI, blue). (A–C) While cells infected with ataxin 3 27Q presented a strong calpastatin immunoreactivity, when ataxin 3 72Q was
injected (D–F), the cells in which intranuclear inclusions were present showed nearly no calpastatin immunolabelling. (F) Even in the same
hemisphere, in opposition to the cell indicated with an arrow, the cells with intranuclear inclusions (indicated with arrow heads) did not
overexpress calpastatin, suggesting that the endogenous calpain inhibitor was depleted upon mutant ataxin 3 expression. Western blot
analysis with anti-calpastatin antibody (Ab H300) revealed a decrease of calpastatin levels in mutant ataxin 3 transduced hemisphere
compared with its contralateral hemisphere (G); and also in lysates obtained from dissected cerebella of a Machado–Joseph disease
transgenic mouse model (n = 5; H) and from dentate nucleus of Patients O, W and K with Machado–Joseph disease (I). (J) Quantitative
analysis of calpastatin immunoreactivity (n = 4, **P5 0.01). (K–M) Densitometric quantification of calpastatin levels, shown in panels
G–I, respectively. MJD = Machado–Joseph disease; SEM = standard error of the mean.
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C-terminal fragment simultaneously carrying the nuclear localiza-
tion signal and the expanded polyglutamine tract of ataxin 3 from
the cytoplasm to the nucleus. Altogether, calpain activity is
required for mutant ataxin 3 translocation to the nucleus, and
this effect is antagonized by the presence of calpastatin.
Finally, our studies suggest that upon mutant ataxin 3 expres-
sion calpastatin is depleted (Fig. 6), in accordance to what was
observed in models of Alzheimer’s disease, where the progression
is propelled by a marked depletion of calpastatin, upstream of
calpain activation (Rao et al., 2008). Calpastatin depletion was
observed not only in the lentiviral mouse model, but also in a
mouse model of Machado–Joseph disease (Torashima et al.,
2008; Oue et al., 2009) and in human brain tissue. Rather than
simply its consequence, we speculate that calpastatin depletion
may progressively lead to calpain overactivation. Our results sug-
gest that calpain activation promotes mutant ataxin 3 cleavage,
which in turn translocates to the nucleus and aggregates, and that
during this process calpastatin might also be cleaved, further con-
tributing to calpain overactivation. This observation may also ex-
plain the larger diameter of mutant ataxin 3 inclusions in
transgenic mice overexpressing calpastatin than in mice infected
with AAV2-calpastatin (Fig. 4). In this experiment, lower calpas-
tatin overexpression levels may have been insufficient to overcome
calpastatin depletion, and to inhibit and prevent nuclear
aggregation.
In conclusion, we established the connection in vivo between
mutant ataxin 3 proteolysis by calpains, fragment production and
nuclear localization, which contributes to the elucidation of the
pathogenic mechanism of Machado–Joseph disease.
Furthermore, we show that calpastatin, the endogenous
calpain-specific inhibitor, is able to block this mechanism, prevent-
ing nuclear translocation of mutant ataxin 3, consequent aggre-
gation and nuclear toxicity. Therefore, these findings indicate that
calpains are promising targets for therapeutic intervention in
Machado–Joseph disease.
Acknowledgements
The authors thank Dr Luı´sa Cortes for expert technical assistance
with confocal microscopy, Dr Takaomi Saido for providing the
calpastatin transgenic animals, Dr Robert Siman for providing the
antibody to calpain-cleaved -spectrin (Ab 38) and Dr Hirokazu
Hirai for providing the transgenic Machado–Joseph disease mouse
model.
Funding
This work was funded by The Portuguese Foundation for Science
and Technology, references PTDC/SAU-NEU/099307/2008, The
Richard Chin and Lilly Lock Research Fund, Association Franc¸aise
de Myopathies (AFM) and the National Ataxia Foundation (NAF).
Ana Teresa Simo˜es and Ne´lio Gonc¸alves were supported by the
Portuguese Foundation for Science and Technology, Fellowships
SFRH/BD/33186/2007 and SFRH/BD/38636/2007.
References
Alves S, Regulier E, Nascimento-Ferreira I, Hassig R, Dufour N,
Koeppen A, et al. Striatal and nigral pathology in a lentiviral rat
model of Machado–Joseph disease. Hum Mol Genet 2008; 17:
2071–83.
Antony PM, Mantele S, Mollenkopf P, Boy J, Kehlenbach RH, Riess O,
et al. Identification and functional dissection of localization signals
within ataxin-3. Neurobiol Dis 2009; 36: 280–92.
Berke SJ, Schmied FA, Brunt ER, Ellerby LM, Paulson HL.
Caspase-mediated proteolysis of the polyglutamine disease protein
ataxin-3. J Neurochem 2004; 89: 908–18.
Bichelmeier U, Schmidt T, Hubener J, Boy J, Ruttiger L, Habig K, et al.
Nuclear localization of ataxin-3 is required for the manifestation of
symptoms in SCA3: in vivo evidence. J Neurosci 2007; 27: 7418–28.
Breuer P, Haacke A, Evert BO, Wullner U. Nuclear aggregation of
polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic
quality control. J Biol Chem 2010; 285: 6532–7.
Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative pro-
tein ataxin-3 binds polyubiquitylated proteins and has ubiquitin prote-
ase activity. Hum Mol Genet 2003; 12: 3195–205.
Chai Y, Berke SS, Cohen RE, Paulson HL. Poly-ubiquitin binding by the
polyglutamine disease protein ataxin-3 links its normal function to
protein surveillance pathways. J Biol Chem 2004; 279: 3605–11.
Colomer Gould VF, Goti D, Pearce D, Gonzalez GA, Gao H, Bermudez
de Leon M, et al. A mutant ataxin-3 fragment results from
processing at a site N-terminal to amino acid 190 in brain of
Machado–Joseph disease-like transgenic mice. Neurobiol Dis 2007;
27: 362–9.
de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N. Lentiviral-
mediated delivery of mutant huntingtin in the striatum of rats induces
a selective neuropathology modulated by polyglutamine repeat size,
huntingtin expression levels, and protein length. J Neurosci 2002; 22:
3473–83.
de Almeida LP, Zala D, Aebischer P, Deglon N. Neuroprotective effect of
a CNTF-expressing lentiviral vector in the quinolinic acid rat model of
Huntington’s disease. Neurobiol Dis 2001; 8: 433–46.
Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K. Ataxin-3 inter-
actions with rad23 and valosin-containing protein and its associ-
ations with ubiquitin chains and the proteasome are consistent with
a role in ubiquitin-mediated proteolysis. Mol Cell Biol 2003; 23:
6469–83.
Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haiem L, et al. A
mutant ataxin-3 putative-cleavage fragment in brains of Machado–
Joseph disease patients and transgenic mice is cytotoxic above a critical
concentration. J Neurosci 2004; 24: 10266–79.
Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor:
the DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23:
435–47.
Haacke A, Broadley SA, Boteva R, Tzvetkov N, Hartl FU, Breuer P.
Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical
for aggregation and sequestration of non-expanded ataxin-3. Hum
Mol Genet 2006; 15: 555–68.
Haacke A, Hartl FU, Breuer P. Calpain inhibition is sufficient to suppress
aggregation of polyglutamine-expanded ataxin-3. J Biol Chem 2007;
282: 18851–6.
Higuchi M, Tomioka M, Takano J, Shirotani K, Iwata N, Masumoto H,
et al. Distinct mechanistic roles of calpain and caspase activation in
neurodegeneration as revealed in mice overexpressing their specific
inhibitors. J Biol Chem 2005; 280: 15229–37.
Hubener J, Vauti F, Funke C, Wolburg H, Ye Y, Schmidt T, et al.
N-terminal ataxin-3 causes neurological symptoms with inclusions,
endoplasmic reticulum stress and ribosomal dislocation. Brain 2011;
134: 1925–42.
Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A.
Expanded polyglutamine in the Machado–Joseph disease protein in-
duces cell death in vitro and in vivo. Nat Genet 1996; 13: 196–202.
2438 | Brain 2012: 135; 2428–2439 A. T. Simo˜es et al.
Jung J, Xu K, Lessing D, Bonini NM. Preventing Ataxin-3 protein cleav-
age mitigates degeneration in a Drosophila model of SCA3. Hum Mol
Genet 2009; 18: 4843–52.
Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M,
Katayama S, et al. CAG expansions in a novel gene for Machado–
Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8: 221–8.
Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, et al.
Excitation-induced ataxin-3 aggregation in neurons from patients with
Machado–Joseph disease. Nature 2011; 480: 543–6.
Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M. Differential transgene
expression in brain cells in vivo and in vitro from AAV-2 vectors with
small transcriptional control units. Virology 2003; 311: 89–95.
Liu J, Liu MC, Wang KK. Calpain in the CNS: from synaptic function to
neurotoxicity. Sci Signal 2008; 1: re1.
Macedo-Ribeiro S, Cortes L, Maciel P, Carvalho AL. Nucleocytoplasmic
shuttling activity of ataxin-3. PLoS One 2009; 4: e5834.
Marfori M, Mynott A, Ellis JJ, Mehdi AM, Saunders NF, Curmi PM, et al.
Molecular basis for specificity of nuclear import and prediction of nu-
clear localization. Biochim Biophys Acta 2011; 1813: 1562–77.
Mauri PL, Riva M, Ambu D, De Palma A, Secundo F, Benazzi L, et al.
Ataxin-3 is subject to autolytic cleavage. FEBS J 2006; 273:
4277–86.
Mueller T, Breuer P, Schmitt I, Walter J, Evert BO, Wullner U.
CK2-dependent phosphorylation determines cellular localization and
stability of ataxin-3. Hum Mol Genet 2009; 18: 3334–43.
Oue M, Mitsumura K, Torashima T, Koyama C, Yamaguchi H, Furuya N,
Hirai H. Characterization of mutant mice that express polyglutamine in
cerebellar Purkinje cells. Brain Res 2009; 1255: 9–17.
Paulson HL, Das SS, Crino PB, Perez MK, Patel SC, Gotsdiner D, et al.
Machado–Joseph disease gene product is a cytoplasmic protein widely
expressed in brain. Ann Neurol 1997a; 41: 453–62.
Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH,
Das SS, et al. Intranuclear inclusions of expanded polyglutamine pro-
tein in spinocerebellar ataxia type 3. Neuron 1997b; 19: 333–44.
Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH,
et al. Marked calpastatin (CAST) depletion in Alzheimer’s disease ac-
celerates cytoskeleton disruption and neurodegeneration: neuroprotec-
tion by CAST overexpression. J Neurosci 2008; 28: 12241–54.
Reina CP, Zhong X, Pittman RN. Proteotoxic stress increases nuclear
localization of ataxin-3. Hum Mol Genet 2010; 19: 235–49.
Roberts-Lewis JM, Savage MJ, Marcy VR, Pinsker LR, Siman R.
Immunolocalization of calpain I-mediated spectrin degradation to vul-
nerable neurons in the ischemic gerbil brain. J Neurosci 1994; 14:
3934–44.
Rubinsztein DC, Wyttenbach A, Rankin J. Intracellular inclusions, patho-
logical markers in diseases caused by expanded polyglutamine tracts? J
Med Genet 1999; 36: 265–70.
Scheel H, Tomiuk S, Hofmann K. Elucidation of ataxin-3 and ataxin-7
function by integrative bioinformatics. Hum Mol Genet 2003; 12:
2845–52.
Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G,
Laccone F, et al. An isoform of ataxin-3 accumulates in the nucleus
of neuronal cells in affected brain regions of SCA3 patients. Brain
Pathol 1998; 8: 669–79.
Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S. Promoters and
serotypes: targeting of adeno-associated virus vectors for gene transfer
in the rat central nervous system in vitro and in vivo. Exp Physiol 2005;
90: 53–9.
Sudarsky L, Coutinho P. Machado–Joseph disease. Clin Neurosci 1995; 3:
17–22.
Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O.
Soluble polyglutamine oligomers formed prior to inclusion body for-
mation are cytotoxic. Hum Mol Genet 2008; 17: 345–56.
Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S, et al.
Calpain mediates excitotoxic DNA fragmentation via mitochondrial
pathways in adult brains: evidence from calpastatin mutant mice. J
Biol Chem 2005; 280: 16175–84.
Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, et al.
Lentivector-mediated rescue from cerebellar ataxia in a mouse model
of spinocerebellar ataxia. EMBO Rep 2008; 9: 393–399.
Walsh R, Storey E, Stefani D, Kelly L, Turnbull V. The roles of proteolysis
and nuclear localisation in the toxicity of the polyglutamine diseases. A
review. Neurotox Res 2005; 7: 43–57.
Wang G, Sawai N, Kotliarova S, Kanazawa I, Nukina N. Ataxin-3, the
MJD1 gene product, interacts with the two human homologs of yeast
DNA repair protein RAD23, HHR23A and HHR23B. Hum Mol Genet
2000; 9: 1795–803.
Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, et al.
Recombinant adeno-associated virus purification using novel methods
improves infectious titer and yield. Gene Ther 1999; 6: 973–85.
Inhibition of calpains relieves MJD/SCA3 Brain 2012: 135; 2428–2439 | 2439
